HEMEX is particularly inspired by the hard-working women who push boundaries to create innovative healthcare solutions. Dedicated and powerful female leaders enrich the diversity of our Swiss start-up portfolio. Today, we would like to introduce five remarkable female role models to you.
In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”. As a founder and […]
Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize. The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in […]
In the battle of fighting against COVID-19, a rapid test is crucial to understand the spread of the pandemic. The Swiss start-up LiVET that originally developed diagnostic tests for respiratory diseases in horses has accelerated their platforms to detect COVID-19 in human samples, establishing a newly incorporated company ender diagnostics ag. Undeniably, ender is a […]
Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. HEMEX AG is a privately-owned Swiss investment and consulting company headquartered […]
On 31 December 2019, the World Health Organization (WHO) received the first case report about pneumonia of unknown cause in Wuhan, China1. Despite draconian containment measures such as lockdown and air travel bans in many countries, as of 4 June 2020, the COVID-19 pandemic has caused more than 6.6 million infections worldwide and the death […]
Scailyte™ is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data.Over the past 3 years, we have established ScaiVision™, a proprietary data analytics platform for clinical research, which enables us to achieve groundbreaking discoveries in multiple disease areas. We have validated our approach by […]